Anti-Scl-70 Antibodies - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Anti-Scl-70 Antibodies

The Experts below are selected from a list of 792 Experts worldwide ranked by ideXlab platform

Anti-Scl-70 Antibodies – Free Register to Access Experts & Abstracts

Aki Hietaharju – One of the best experts on this subject based on the ideXlab platform.

  • British Journal of Rheumatology 1994;33:323-326 ASSOCIATION OF HLA ANTIGENS WITH Anti-Scl-70Antibodies AND CLINICAL MANIFESTATIONS OF SYSTEMIC SCLEROSIS (SCLERODERMA)
    , 2016
    Co-Authors: Marja Hietarinta, Jarmo Ilonen, F O. Lassila, Aki Hietaharju

    Abstract:

    Thirty patients with systemic sclerosis (scleroderma) and 188 healthy controls were studied for class I and class II MHC antigens. All patients with scleroderma fulfilled the ARA preliminary criteria for systemic sclerosis. The frequencies of HLA antigens B8, DR3 and DR52 were higher in patients with scleroderma as compared with controls. Ten patients had Anti-Scl-70 Antibodies, and four of them (40%) had HLA-DR5 antigen compared to 19 of 188 controls (10%), P = 0.013. The relative risk for DR5 in Anti-Scl-70-positive patients was 3.6 compared to 1.6 of DQ3 suggesting the primary signifi-cance of DR5 compared to DQ related factors. Patients with neurological manifestations had higher frequencies of B8 and DR3 than those with no neurological manifestations of scleroderma. Our results support the view that immunogenetic background is associated with different clinical subsets of systemic sclerosis. KEY WORDS: Scleroderma, Systemic sclerosis, HLA antigens, Anti-Scl-70 Antibodies. THE aetiology of systemic sclerosis (scleroderma) is unknown, but association of several different anti-bodies with clinical subsets of scleroderma suggests an immunologic pathogenesis. Environmental factors are involved in some cases, as for example those associated with vinyl chloride exposure. Immunogenetic associ

  • ASSOCIATION OF HLA ANTIGENS WITH Anti-Scl-70Antibodies AND CLINICAL MANIFESTATIONS OF SYSTEMIC SCLEROSIS (SCLERODERMA)
    Rheumatology, 1994
    Co-Authors: Marja Hietarinta, Jarmo Ilonen, Olli Lassila, Aki Hietaharju

    Abstract:

    Thirty patients with systemic sclerosis (scleroderma) and 188 healthy controls were studied for class I and class II MHC antigens. All patients with scleroderma fulfilled the ARA preliminary criteria for systemic sclerosis. The frequencies of HLA antigens B8, DR3 and DR52 were higher in patients with scleroderma as compared with controls. Ten patients had Anti-Scl-70 Antibodies, and four of them (40%) had HLA-DR5 antigen compared to 19 of 188 controls (10%), P=0.013. The relative risk for DR5 in Anti-Scl-70-positive patients was 3.6 compared to 1.6 of DQ3 suggesting the primary significance of DR5 compared to DQ related factors. Patients with neurological manifestations had higher frequencies of B8 and DR3 than those with no neurological manifestations of scleroderma

  • Association of anti-U1RNP- and Anti-Scl-70Antibodies with neurological manifestations in systemic sclerosis (scleroderma).
    Scandinavian Journal of Rheumatology, 1994
    Co-Authors: Marja Hietarinta, Olli Lassila, Aki Hietaharju

    Abstract:

    Thirty-one patients with SSc were studied. Eleven patients had Anti-Scl-70-, six had anti-UIRNP-, three had anticentromere Antibodies, and one both Anti-Scl-70-and anticentromere Antibodies. Eleven patients (35%) had neurological findings (trigeminal neuropathy, polyneuropathy. in some with myopathy). Eight of these patients (73%) had either anti-UIRNP-or Anti-Scl-70Antibodies in their serum. These findings suggest that neurological manifestations are not as uncommon in SSc as previously reported. There are probably subgroups of patients who are more prone to neurological manifestations of scleroderma (mostly patients with anti-UIRNP and possibly those with Anti-Scl-70 Antibodies).

X Bossuyt – One of the best experts on this subject based on the ideXlab platform.

  • Anti-PM/Scl-100 and anti-RNA-polymerase III Antibodies in scleroderma
    Clinica Chimica Acta, 2010
    Co-Authors: L Maes, D Blockmans, P Verschueren, R Westhovens, K Op De Beéck, P Vermeersch, K Van Den Bergh, R W Burlingame, M Mahler, X Bossuyt

    Abstract:

    Abstract Background Systemic sclerosis (SSc) is a rare autoimmune disease characterized by the presence of various autoAntibodies, including anti-centromere, anti-topoisomerase (Scl-70), anti-PM/Scl-100, and anti-RNA-polymerase III (RNA Pol-III) Antibodies. Recently, new ELISA based immunoassays have become available for the detection of anti-PM/Scl and anti-RNA Pol-lII Antibodies. Objective We studied the prevalence and clinical association of anti-PM/Scl-100 (PM1-Alpha) and anti-RNA Pol-III Antibodies. Methods Antibodies to PM1-Alpha and RNA Pol-III were measured by ELISA (DR. Fooke Laboratories and Inova Diagnostics, respectively) in 242 patients with various connective tissue diseases (CTD) (including 70 SSc patients) and in 36 non-CTD controls. Results Low levels of PM1-Alpha Antibodies were found in various CTDs, whereas high levels were exclusively found in SSc, dermatomyositis and polymyositis, albeit at low frequency (4.7%). Anti-RNA Pol-III Antibodies were found in 7% of SSc and in 1% of non-CTD and CTD controls. Anti-centromere and Anti-Scl-70 Antibodies were found in 37% and 21% of SSc patients, respectively. Anti-centromere Antibodies were associated with limited cutaneous SSc and Anti-Scl-70 Antibodies with diffuse cutaneous SSc and interstitial lung disease. Because of the low number of samples positive for anti-PM/Scl-100 or RNA Pol-III Antibodies, no clinical feature was statistically correlated with the presence of either reactivity, but taken together the presence of either antibody was correlated with interstitial lung disease. Anti-PM1-Alpha and anti-RNA Pol-III Antibodies were mutually exclusive with Anti-Scl-70 Antibodies. Conclusions At high levels, anti-PM/Scl-100 Antibodies were associated with SSc, PM, and DM, albeit at low frequency. Anti-RNA Pol-III Antibodies were associated with SSc (in 7%) with high specificity.

  • Anti-PM/Scl-100 and anti-RNA-polymerase III Antibodies in scleroderma.
    Clinica chimica acta; international journal of clinical chemistry, 2010
    Co-Authors: L Maes, D Blockmans, P Verschueren, R Westhovens, K Op De Beéck, P Vermeersch, K Van Den Bergh, R W Burlingame, M Mahler, X Bossuyt

    Abstract:

    Systemic sclerosis (SSc) is a rare autoimmune disease characterized by the presence of various autoAntibodies, including anti-centromere, anti-topoisomerase (Scl-70), anti-PM/Scl-100, and anti-RNA-polymerase III (RNA Pol-III) Antibodies. Recently, new ELISA based immunoassays have become available for the detection of anti-PM/Scl and anti-RNA Pol-lII Antibodies.
    We studied the prevalence and clinical association of anti-PM/Scl-100 (PM1-Alpha) and anti-RNA Pol-III Antibodies.
    Antibodies to PM1-Alpha and RNA Pol-III were measured by ELISA (DR. Fooke Laboratories and Inova Diagnostics, respectively) in 242 patients with various connective tissue diseases (CTD) (including 70 SSc patients) and in 36 non-CTD controls.
    Low levels of PM1-Alpha Antibodies were found in various CTDs, whereas high levels were exclusively found in SSc, dermatomyositis and polymyositis, albeit at low frequency (4.7%). Anti-RNA Pol-III Antibodies were found in 7% of SSc and in 1% of non-CTD and CTD controls. Anti-centromere and Anti-Scl-70 Antibodies were found in 37% and 21% of SSc patients, respectively. Anti-centromere Antibodies were associated with limited cutaneous SSc and Anti-Scl-70 Antibodies with diffuse cutaneous SSc and interstitial lung disease. Because of the low number of samples positive for anti-PM/Scl-100 or RNA Pol-III Antibodies, no clinical feature was statistically correlated with the presence of either reactivity, but taken together the presence of either antibody was correlated with interstitial lung disease. Anti-PM1-Alpha and anti-RNA Pol-III Antibodies were mutually exclusive with Anti-Scl-70 Antibodies.
    At high levels, anti-PM/Scl-100 Antibodies were associated with SSc, PM, and DM, albeit at low frequency. Anti-RNA Pol-III Antibodies were associated with SSc (in 7%) with high specificity.
    Copyright 2010 Elsevier B.V. All rights reserved.

  • Evaluation of a Dot-Blot Method for Identification of Antibodies against Extractable Nuclear Antigens and Anti-Cytoplasmic Antibodies
    Clinical Chemistry, 1999
    Co-Authors: Alex Mewis, Godelieve Mariën, Norbert Blanckaert, X Bossuyt

    Abstract:

    Antibodies against extractable nuclear antigens (ENAs) are useful diagnostic markers for various autoimmune diseases. Anti-SSA and anti-SSB Antibodies are found in Sjogren Syndrome (SS), anti-Sm Antibodies are found in systemic lupus erythematosus (SLE), anti-RNP Antibodies are found in mixed connective tissue disease (MCTD), and Anti-Scl-70 Antibodies are found in scleroderma. Antibodies against cytoplasmic Jo-1 and M2 are helpful markers for the diagnosis of, respectively, polymyositis and primary biliary cirrhosis. The Antibodies can be identified by either counter immunoelectrophoresis (CIE) or immunoblotting. These techniques, however, are time-consuming, technically demanding, and do not provide for fast turnaround times. Over the last few years, alternative …

Marius Teodorescu – One of the best experts on this subject based on the ideXlab platform.

  • Anti–topoisomerase I (Anti–Scl‐70) Antibodies in patients with systemic lupus erythematosus
    Arthritis & Rheumatism, 2001
    Co-Authors: Hélène A. Gussin, Georghe P. Ignat, John Varga, Marius Teodorescu

    Abstract:

    Objective

    To investigate the presence and clinical significance of anti–Scl-70 Antibodies in patients with systemic lupus erythematosus (SLE).

    Methods

    Levels of Antibodies against Scl-70 were determined by a commercial clinical enzyme-linked immunosorbent assay (ELISA) during routine evaluation. Results were verified by an additional ELISA with a characterized bovine Scl-70, by ELISA with a recombinant human topoisomerase I, by Western blot, and by double diffusion in agar gel. Disease activity was estimated retrospectively by the Systemic Lupus Activity Measure (SLAM).

    Results

    Of 128 consecutive SLE patients, 25% were positive for anti–Scl-70 antibody; this antibody activity was cognate in nature. No SLE patient could be classified as also having systemic sclerosis. The levels of anti–Scl-70 were significantly correlated with the SLAM score for the entire cohort (r = 0.563, P < 0.001) and for 7 individual patients with multiple longitudinal measurements (r = 0.755–0.951, P < 0.001; n = 6) (r = 0.378, P < 0.05; n = 1). A significant correlation was also found between the levels of anti–Scl-70 and anti–double-stranded DNA Antibodies (r = 0.558, P < 0.001). Patients with anti–Scl-70 had significantly higher risk of pulmonary hypertension (P < 0.01) and renal involvement (P < 0.001) than patients without this antibody. Conclusion Anti–Scl-70 antibody is present in a significant subset of patients with SLE. For this subset, it offers a good correlate of disease activity and suggests increased risk for pulmonary hypertension and nephritis.

  • Anti-topoisomerase I (Anti-Scl-70) Antibodies in patients with systemic lupus erythematosus.
    Arthritis and rheumatism, 2001
    Co-Authors: Hélène A. Gussin, Georghe P. Ignat, John Varga, Marius Teodorescu

    Abstract:

    Objective

    To investigate the presence and clinical significance of anti–Scl-70 Antibodies in patients with systemic lupus erythematosus (SLE).

    Methods

    Levels of Antibodies against Scl-70 were determined by a commercial clinical enzyme-linked immunosorbent assay (ELISA) during routine evaluation. Results were verified by an additional ELISA with a characterized bovine Scl-70, by ELISA with a recombinant human topoisomerase I, by Western blot, and by double diffusion in agar gel. Disease activity was estimated retrospectively by the Systemic Lupus Activity Measure (SLAM).

    Results

    Of 128 consecutive SLE patients, 25% were positive for anti–Scl-70 antibody; this antibody activity was cognate in nature. No SLE patient could be classified as also having systemic sclerosis. The levels of anti–Scl-70 were significantly correlated with the SLAM score for the entire cohort (r = 0.563, P < 0.001) and for 7 individual patients with multiple longitudinal measurements (r = 0.755–0.951, P < 0.001; n = 6) (r = 0.378, P < 0.05; n = 1). A significant correlation was also found between the levels of anti–Scl-70 and anti–double-stranded DNA Antibodies (r = 0.558, P < 0.001). Patients with anti–Scl-70 had significantly higher risk of pulmonary hypertension (P < 0.01) and renal involvement (P < 0.001) than patients without this antibody. Conclusion Anti–Scl-70 antibody is present in a significant subset of patients with SLE. For this subset, it offers a good correlate of disease activity and suggests increased risk for pulmonary hypertension and nephritis.